RxDoctor Payments Data

Michael Walls, MD

Cardiovascular Disease · Indianapolis, INNPI 1497877526

Payments from drug & device makers

$2,690in general payments, 2019–2025

Across 23 payments — averaging $116.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$2K
  • Boston Scientific$128
  • Novartis$62
  • Amgen$21

What the payments were for

  • Consulting fees$30614%
  • Travel & lodging$87640%
  • Food & beverage$1,00846%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Heartflow, Inc.17$2,478
Boston Scientific2$128
Novartis3$62
Amgen1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,690 in reported general payments places this provider in the 45th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$154,074
Medicare patients
1,255
Services billed
2,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$543,837
EntrestoSacubitril/Valsartan219$255,741
JardianceEmpagliflozin185$193,560
XareltoRivaroxaban98$142,112
Repatha SureclickEvolocumab58$87,811
MultaqDronedarone Hcl30$35,561
VascepaIcosapent Ethyl21$12,153
NexletolBempedoic Acid18$10,356
Rosuvastatin Calcium729$8,135
Ezetimibe355$7,324
Metoprolol Succinate622$6,974
Atorvastatin Calcium671$5,827
Ranolazine ErRanolazine33$4,418
Valsartan192$3,664
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$62$255,741219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →